ArticleBMC women's health2026
Long-term effects of ospemifene on densitometric and bone metabolism biomarkers in postmenopausal women reporting Vulvar and Vaginal Atrophy (VVA).
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ospemifene (OSP), a Selective Estrogen Receptor Modulator (SERM), is recommended for treating vulvovaginal atrophy (VVA) in postmenopausal women (PMW). Previous 12 mm data suggested that OSP therapy had beneficial effects on bone mineral and biochemical markers in a similar VVA population.Objective This real-life study sought to evaluate the long-term effects (24 mm) of Ospemifene therapy on bone metabolism and mineral parameters compared with a control group.Methods PMW aged 40–64 years with VVA symptoms and a baseline bone health assessment were included in the study. A total of 72 subjects treated with Ospemifene 60 mg/day (OSPG) were compared with a control group (CG, n = 49) over 24 months. Bone mineral density (BMD) at the femoral neck, total femur, and lumbar spine was assessed by DEXA, and biochemical markers of bone metabolism were measured in blood samples at baseline and 24 months.Results In the control group, BMD and T-scores significantly decreased at the femoral neck (-0,029; -0,26) and lumbar spine (-0,049; -0,32). In contrast, the OSPG showed no significant decline in BMD at any measured site (+ 0,005; +0,005;+0,009). The CG also exhibited a significant increase in bone turnover markers (BAP: +2.7; OC: +4.2). Conversely, the OSPG demonstrated significant reductions in bone alkaline phosphatase (BAP: -2.5) and osteocalcin (OC: -2.8), biomarkers of bone formation.Conclusions Long-term ospemifene treatment effectively preserves bone health at all sites, counteracting the expected menopause-associated bone loss and protecting against bone density reduction in healthy PMW with VVA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.